ArticleJACC. Advances2026
Oral Anticoagulants and Risk of Bleeding and Death in Cancer-Associated Venous Thromboembolism.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAmong patients with cancer-associated VTE (Ca-VTE), anticoagulant choice may impact outcomes such as hospitalized bleeding and death, with potential differences across different cancer sites.
objectivesThis study aimed to evaluate the risks of hospitalized bleeding and death by oral anticoagulant (OAC) prescribed (ie, apixaban, rivaroxaban, and warfarin), overall and by cancer site.
methodsPatients with Ca-VTE aged ≥65 years were identified from the U.S. Medicare 20% sample databases for years 2011 to 2019. Algorithms based on International Classification of Diseases codes were used to define venous thromboembolism, cancer site, comorbidities, and hospitalized bleeding. Cox regression was used, with follow-up restricted to 6 months.
resultsAmong the 30,342 patients with Ca-VTE who filled prescriptions for OACs (apixaban: 6,546; rivaroxaban: 7,936; warfarin: 15,860), 634 experienced incident hospitalized bleeding and 5,977 died within 6 months of incident venous thromboembolism. Overall, the hospitalized bleeding HR (95% CI) for apixaban vs rivaroxaban was 0.68 (0.56-0.83). This pattern was present for most cancer sites (ie, breast, colon, lung, and prostate), though precision was poor and associations were not statistically significant. No clear pattern emerged when comparing apixaban or rivaroxaban to warfarin. For mortality there was no association overall (HR apixaban vs rivaroxaban: 0.99 [0.91-1.08]). Results were generally similar in analyses stratified by age category, sex, prevalent kidney disease status, and metastatic cancer status.
conclusionsAmong patients with Ca-VTE, apixaban may be associated with lower risk of hospitalized bleeding than rivaroxaban. Additional research is needed to understand associations of OAC prescribed with all-cause mortality among patients with Ca-VTE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.